Oncosil will be a run-away success both for patients and shareholders if they:
- can show a viable difference to patient outcomes, either stand-alone or in combo with chemo
- be readily available in Europe and Australasia, multi supply chain and better buying price
- are respected and adopted by decision makers who pay for it
- have a large hospital network that can make the treatment available ( ie training and licensing )
- have a driven and experienced team to drive success
- have a leader / CEO who has the experience and is well networked in the field plus the board
Where are we with this I ask you ?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.160(15.7%) |
Mkt cap ! $16.78M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.18 | $1.03 | $42.42K | 39.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14466 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 2775 | 1 |
View Market Depth
| Last trade - 13.33pm 26/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |